Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 3:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 276 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: cannabidiol (CBD) Clear all
Terminated Phase 2 Interventional Results available

A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Participants With Prader-Willi Syndrome

NCT03458416
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Cannabidiol Oral Solution
Drug
Lead sponsor
Radius Pharmaceuticals, Inc.
Industry
Eligibility
8 Years to 17 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 25, 2026, 3:52 PM EDT
Completed Phase 3 Interventional Results available

Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7)

NCT02953548
View directory record Official record
Conditions
Infantile Spasms
Interventions
GWP42003-P
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Month to 24 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Little Rock, Arkansas • Winston-Salem, North Carolina • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Sep 25, 2026, 3:52 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Assess the Effect of Cannabidiol Oil on Pain After Ureteroscopy for Kidney Stones

NCT04387617
View directory record Official record
Conditions
Urinary Stone
Interventions
Cannabidiol, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Sep 25, 2026, 3:52 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Wayne State Warriors Marijuana Clinical Research Program: Cannabinoid Adjunct to Prolonged Exposure & Recovery

NCT06222268
View directory record Official record
Conditions
PTSD, Post Traumatic Stress Disorder, Suicide, Cannabis Use
Interventions
Cannabidiol (CBD) only, Placebo only, Delta-9-tetrahydrocannabinol (THC) only, THC:CBD 1:1
Drug
Lead sponsor
Leslie Lundahl
Other
Eligibility
18 Years to 60 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 25, 2026, 3:52 PM EDT
Active, not recruiting Phase 4 Interventional

Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

NCT05044819
View directory record Official record
Conditions
Lennox Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex
Interventions
Cannabidiol
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Year and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
26
States / cities
Little Rock, Arkansas • Downey, California • Long Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 25, 2026, 3:52 PM EDT
Terminated Phase 2 Interventional Results available

Cannabidiol Oral Solution for Treatment of Refractory Infantile Spasms

NCT02551731
View directory record Official record
Conditions
Spasms, Infantile
Interventions
Cannabidiol Oral Solution
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
6 Months to 36 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Sep 25, 2026, 3:52 PM EDT
Recruiting Phase 2 Interventional

Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype

NCT05269628
View directory record Official record
Conditions
Multiple Sclerosis, Sleep, Pain
Interventions
Cannabidiol (CBD), Tetrahydrocannabinol (THC), Placebo CBD, Placebo THC
Drug
Lead sponsor
Tiffany J. Braley, MD, MS
Other
Eligibility
18 Years to 65 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 25, 2026, 3:52 PM EDT
Completed Early Phase 1 Interventional Results available

Safety and Tolerability of Cannabidiol Among Persons With Opioid Use Disorder Receiving Methadone or Buprenorphine

NCT05076370
View directory record Official record
Conditions
Addiction
Interventions
CBD Day 1, CBD Day 2, CBD Day 3
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 25, 2026, 3:52 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Cannabis Use, Cognition, and the Endocannabinoid System in HIV

NCT04883255
View directory record Official record
Conditions
HIV-1-infection
Interventions
10 mg Δ9-tetrahydrocannabinol (THC), 600 mg cannabidiol (CBD), Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 25, 2026, 3:52 PM EDT
Recruiting Not applicable Interventional

MIVetsCan: Can-Coach Trial (Phase 2)

NCT06283862
View directory record Official record
Conditions
Chronic Pain
Interventions
Educational Session
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 25, 2026, 3:52 PM EDT
Recruiting Phase 1Phase 2 Interventional

Assessing the Mechanisms and Impact of a Novel Cannabinoid Product for Gynecologic Pain

NCT07728695
View directory record Official record
Conditions
Endometriosis, Adenomyosis, Chronic Pelvic Inflammatory Disease
Interventions
Custom-formulated, high-CBD study product, Placebo
Drug
Lead sponsor
Staci Gruber, Ph.D.
Other
Eligibility
21 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 25, 2026, 3:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cannabidiol Effects on Blood Alcohol Level and Intoxication

NCT06105138
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
200mg Cannabidiol oral solution, 30mg Cannabidiol oral solution, Placebo
Dietary Supplement
Lead sponsor
Colorado State University
Other
Eligibility
21 Years to 60 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Sep 25, 2026, 3:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Investigation of the Pharmacokinetic Profile of CBD - Phase 1 ANANDA

NCT05023070
View directory record Official record
Conditions
Healthy
Interventions
Cannabidiol
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Sep 25, 2026, 3:52 PM EDT
Completed Phase 1 Interventional

Cannabidiol (CBD) to 27 Patients (Aged 2 Years - 19 Years) With Drug Resistant Epilepsy

NCT02286986
View directory record Official record
Conditions
Epilepsy
Interventions
Cannabidiol
Drug
Lead sponsor
University of Utah
Other
Eligibility
2 Years to 25 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Sep 25, 2026, 3:52 PM EDT
Recruiting Phase 3 Interventional

Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder

NCT07123467
View directory record Official record
Conditions
Generalized Anxiety Disorder (GAD), Anxiety Disorders
Interventions
Low-Dose Cannabidiol, Placebo Matched to Moderate-Dose Cannabidiol, Moderate-Dose Cannabidiol, Placebo Matched to Low-Dose Cannabidiol
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 45 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 25, 2026, 3:52 PM EDT
Completed Phase 1 Interventional Results available

Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer

NCT04428203
View directory record Official record
Conditions
Prostate Cancer Recurrent, Prostate Cancer, Prostate Adenocarcinoma
Interventions
Epidiolex Oral Liquid Product
Drug
Lead sponsor
Zin W Myint
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Sep 25, 2026, 3:52 PM EDT
Completed Phase 2 Interventional

Cannabidiol as a Treatment for Social Anxiety Disorder (R61)

NCT05571592
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Cannabidiol, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 25, 2026, 3:52 PM EDT
Recruiting Phase 2Phase 3 Interventional

Cannabidiol (CBD) in Pain Reduction for Knee Osteoarthritis

NCT05020028
View directory record Official record
Conditions
Knee Arthritis
Interventions
Cannabidiol (CBD), Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 25, 2026, 3:52 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia

NCT03941288
View directory record Official record
Conditions
Gastroparesis, Dyspepsia
Interventions
Cannabidiol, placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Sep 25, 2026, 3:52 PM EDT
Completed Phase 3 Interventional Results available

An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

NCT02544750
View directory record Official record
Conditions
Tuberous Sclerosis Complex, Seizures
Interventions
GWP42003-P
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Year to 65 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Sep 25, 2026, 3:52 PM EDT
Completed No phase listed Observational

Anxiety Symptoms in Relation to Use of Hemp-derived, Full Spectrum Cannabidiol (CBD)

NCT05023759
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Formula30A Full Spectrum Hemp Cannabidiol 25mg Capsules
Dietary Supplement
Lead sponsor
Formula30A LLC
Industry
Eligibility
21 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
5
States / cities
Denton, Texas • Edinburg, Texas • Forney, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2021 · Synced Sep 25, 2026, 3:52 PM EDT
Completed Phase 2 Interventional Results available

Epidiolex in Obsessive Compulsive Disorder and Related Disorders

NCT04978428
View directory record Official record
Conditions
Obsessive-Compulsive Disorder, Trichotillomania (Hair-Pulling Disorder), Tourette Syndrome, Hoarding Disorder
Interventions
Cannabidiol
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 25, 2026, 3:52 PM EDT
Completed Phase 1 Interventional Results available

University of Alabama at Birmingham (UAB) Pediatric CBD Program

NCT02695537
View directory record Official record
Conditions
Epilepsy, Seizures
Interventions
Epidiolex
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Year to 19 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Sep 25, 2026, 3:52 PM EDT
Not listed Phase 2 Interventional

Using Cannabidiol to Treat Diabetic Peripheral Neuropathy of the Feet

NCT04679545
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
CBD, Placebo
Drug
Lead sponsor
Pure Green
Industry
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bloomfield Township, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 25, 2026, 3:52 PM EDT